![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
DARE Dare Bioscience
- 3.0400
- -0.1300-4.10%
Close Feb 14 16:00 ET
- 3.0400
- 0.00000.00%
Post 18:02 ET
26.45MMarket Cap-5.24P/E (TTM)
3.1325High3.0300Low19.44KVolume3.1200Open3.1700Pre Close59.27KTurnover0.23%Turnover RatioLossP/E (Static)8.70MShares7.560052wk High-17.78P/B26.03MFloat Cap2.670352wk Low--Dividend TTM8.56MShs Float1304.4000Historical High--Div YieldTTM3.23%Amplitude2.6700Historical Low3.0480Avg Price1Lot Size
Dare Bioscience Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
76
9
3
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
59
17
4
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
3
$Dare Bioscience (DARE.US)$ Daré Bioscience Announces Up To $2M NIAID Grant For DARE-HPV Development; Total Non-Dilutive Funding May Reach $12M
Benzinga· 1 min ago
Benzinga· 1 min ago
$Dare Bioscience (DARE.US)$
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Thursday, 6th February at 8:00 am
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management
Essentially all cervical cancer cases worldwide are caused by HPV infec...
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development
Thursday, 6th February at 8:00 am
DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management
Essentially all cervical cancer cases worldwide are caused by HPV infec...
1
$Dare Bioscience (DARE.US)$
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Monday, 16th December at 8:00 am
FSAD is clinically analogous to erectile dysfunction in men.
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA approval for FSAD.
Market research estimates approximately 10 million women in the U.S. are distressed from e...
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Monday, 16th December at 8:00 am
FSAD is clinically analogous to erectile dysfunction in men.
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré's Sildenafil Cream has the potential to receive the first FDA approval for FSAD.
Market research estimates approximately 10 million women in the U.S. are distressed from e...
$Dare Bioscience (DARE.US)$
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience received a $2.5 million grant installment for developing DARE-LARC1, a novel contraceptive technology. This payment is part of a larger $49 million grant agreement, of which $31.8 million has been received to date. DARE-LARC1 represents a potential new category of long-acting, reversible contraceptive featuring...
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience received a $2.5 million grant installment for developing DARE-LARC1, a novel contraceptive technology. This payment is part of a larger $49 million grant agreement, of which $31.8 million has been received to date. DARE-LARC1 represents a potential new category of long-acting, reversible contraceptive featuring...
$Dare Bioscience (DARE.US)$ Reuters
3 mins ago
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
3 mins ago
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
1
$Dare Bioscience (DARE.US)$
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $10.7 million from the Bill & Melinda Gates Foundation. The funding will support two key initiatives: the development of a novel non-hormonal intravaginal contraceptive product candidate and the expansion of clinical sites for the ongoing Ovapr...
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites
Daré Bioscience (NASDAQ: DARE) has secured a grant of up to $10.7 million from the Bill & Melinda Gates Foundation. The funding will support two key initiatives: the development of a novel non-hormonal intravaginal contraceptive product candidate and the expansion of clinical sites for the ongoing Ovapr...
No comment yet
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
kingrotch : thank you for your work
真名有晨 : Thank you very much
Please take care and rest.
iluvpoptarts : sry doc. I'm too busy counting the money your making me too look. muha
IamBadNewz : @Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
Jaguar8 OP IamBadNewz : You have to be patient
View more comments...